Related Experiment Video

Updated: Jul 28, 2026

High-throughput Quantitative Real-time RT-PCR Assay for Determining Expression Profiles of Types I and III Interferon Subtypes
10:00

High-throughput Quantitative Real-time RT-PCR Assay for Determining Expression Profiles of Types I and III Interferon Subtypes

Published on: March 24, 2015

13.9K

Interferon-free therapies for patients with chronic hepatitis C genotype 3 infection: A systematic review

V Gimeno-Ballester1,2, M Buti3, R San Miguel2,4

  • 1Department of Pharmacy, Hospital Universitario Miguel Servet, Zaragoza, Spain.

Journal of Viral Hepatitis
|December 8, 2016
PubMed

Insights

Direct-acting antiviral (DAA) treatment for hepatitis C virus (HCV) genotype 3 infection is improving. New regimens offer higher sustained virological response (SVR) rates, particularly for patients with cirrhosis, making HCV genotype 3 less challenging.

Area of Science:

  • Hepatology
  • Virology
  • Infectious Diseases

Background:

  • Hepatitis C virus (HCV) genotype 3 infection presents unique treatment challenges, with lower direct-acting antiviral (DAA) efficacy and increased risk of disease progression and hepatocellular carcinoma.
  • Current treatment strategies for HCV genotype 3 require optimization to improve outcomes and reduce the burden of this specific viral genotype.

Purpose of the Study:

  • To conduct a comprehensive literature review on the efficacy of interferon-free regimens for treating HCV genotype 3 infection.
  • To evaluate sustained virological response (SVR) rates across different DAA-based treatment regimens in patients with HCV genotype 3, including those with cirrhosis and HIV coinfection.

Main Methods:

  • Systematic literature search of PubMed/Medline, Embase, and Web of Science databases for clinical trials and observational studies.
  • Inclusion of studies involving chronic hepatitis C patients treated with DAAs, with or without ribavirin.
  • Independent evaluation of trials for eligibility, risk of bias, and data extraction, focusing on SVR as the primary outcome.

Main Results:

  • A total of 29 studies encompassing 4068 patients with HCV genotype 3 were included in the review.
  • Regimens like sofosbuvir/velpatasvir for 12 weeks and sofosbuvir/daclatasvir/ribavirin for 12 weeks demonstrated higher SVR rates compared to sofosbuvir/ribavirin for 24 weeks, especially in cirrhotic patients.
  • Sofosbuvir/ledipasvir + ribavirin for 12 weeks achieved an 85% SVR in patients with decompensated cirrhosis, though this subgroup remains challenging.

Conclusions:

  • Treatment outcomes for HCV genotype 3 are rapidly improving with newer interferon-free DAA regimens.
  • HCV genotype 3 may soon be considered a treatable subgroup, with advancements offering better SVR rates, particularly in complex patient populations.
  • Further research into optimal DAA strategies for decompensated cirrhosis patients with HCV genotype 3 is warranted.

Keywords:
chronic hepatitis Cdirect antiviral agentsdrug therapysustained virological responsesystematic reviewviral hepatitis

More Related Videos

Zika Virus Infectious Cell Culture System and the In Vitro Prophylactic Effect of Interferons09:11

Zika Virus Infectious Cell Culture System and the In Vitro Prophylactic Effect of Interferons

Published on: August 23, 2016

21.6K
Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice07:25

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice

Published on: September 25, 2019

7.5K

Related Concept Videos

Gastritis III: Clinical Manifestations and Management01:23

Gastritis III: Clinical Manifestations and Management

The clinical manifestations of gastritis can vary depending on the cause and type of gastritis, but some common symptoms may include the following.
Clinical manifestations of acute gastritis
The patient with acute gastritis may have a rapid onset of symptoms, such as epigastric pain or discomfort, dyspepsia, anorexia, hiccups, or nausea and vomiting, which can last from a few hours to a few days. Erosive or hemorrhagic gastritis may cause bleeding, which may manifest as blood in vomit or as...
Chronic Pancreatitis II: Collaborative Care01:29

Chronic Pancreatitis II: Collaborative Care

The management of chronic pancreatitis is multifaceted, involving a comprehensive approach that includes thorough assessment, diagnostic testing, and a variety of management strategies.
Assessment:
Hepatitis01:25

Hepatitis

Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver. The...
Inhibitors of Viral Protein Synthesis01:30

Inhibitors of Viral Protein Synthesis

Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
Antiviral Nucleoside Inhibitors01:22

Antiviral Nucleoside Inhibitors

Antiviral Nucleoside InhibitorsAntiviral nucleoside inhibitors are structural analogs of natural nucleosides that interfere with viral DNA or RNA synthesis. These compounds selectively target viral polymerases due to their resemblance to host nucleosides, thereby disrupting viral genome replication.Mechanism of Acyclovir ActionAcyclovir is a guanosine analog with a three-carbon acyclic side chain. It selectively targets herpes simplex virus type 1 (HSV-1), herpes simplex virus type 2 (HSV-2),...
Viral Hepatitis I: Introduction01:28

Viral Hepatitis I: Introduction

Viral hepatitis is an inflammatory condition of the liver caused by infection with hepatotropic viruses, most commonly hepatitis A, B, C, D, and E. Despite variations in structure and transmission, all viruses mentioned infect hepatocytes and provoke immune responses that can hinder liver function. Additionally, some non-hepatotropic viruses can also lead to hepatic inflammation.Hepatitis A VirusHepatitis A virus (HAV) is transmitted through the fecal–oral route, typically by ingestion of food...